micro-community-banner
 
Profile Image
  • Add Media
  • Saved

6mo
Healthcare dashboard technologies and data visualization for lipid management: A scoping review - PubMed

Healthcare dashboard technologies and data visualization for lipid management: A scoping review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39574106/

Dashboards are important tools in managing lipid disorders in managing lipid disorders, integrating with educational tools, collaborative care models, and decision support systems. Although they are effective in enhancing population...

Dashboard technologies enhance lipid management by supporting prevention, treatment planning, and decision-making, improving population health and clinical workflows, though patient outcomes and cost impacts need further investigation.

Profile Image
  • Saved

6mo

usually aim post mi for LDL less or equal to 55 mg/dl. Often if maxed out on statin add pcsk9i either Repatha or Praluent depending on insurance approval, and make sure nutrition/CDE are consulted before discharge

Profile Image
  • Saved

6mo

High intensity statin at discharge - with close followup afterward and addition of ezet/PCSK9I/bemp acid if needed.

Profile Image
  • Saved

6mo
Management Aspects of Medical Therapy in Graves Disease - PubMed

Management Aspects of Medical Therapy in Graves Disease - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39701285/

Medical management of GD with antithyroid drug is safe and effective. Long-term use beyond 24 months in patients with elevated thyrotropin receptor antibody is a reasonable alternative option to surgery...

This review highlights antithyroid drugs as the preferred, safe, and effective long-term treatment for Graves disease, emphasizing monitoring, pregnancy considerations, and alternatives to surgery or radioactive iodine.

Profile Image
  • Saved

6mo
GLP-1 Therapies in Metabolic and Hormonal Health: ENDO 2025 Insights

At ENDO 2025, Dr. Monica Laronda (Lurie Children’s Hospital, Northwestern University) highlighted emerging research investigating how GLP-1 therapies and rising obesity rates may influence puberty onset, menarche timing, and sex-specific disease expression—particularly in adolescents with high BMI or genetic susceptibility. She also discussed environmental and epigenetic drivers of endocrine disruption and underscored the need to consider sex as a biological variable in metabolic research. Dr. Shellsea Portillo (St. Louis University Hospital) presented retrospective data indicating that GLP-1–associated weight loss significantly improved testosterone levels in obese men with type 2 diabetes, suggesting a possible avenue for further exploration as a non-hormonal strategy for managing obesity-related hypogonadism. Together, these insights underscore GLP-1’s emerging but preliminary role in reproductive and metabolic endocrine health.

Profile Image